Kenneth M. Boucher

Kenneth M. Boucher, PhD

Languages spoken: English

Academic Information

Departments Adjunct - Population Health Sciences , Primary - Internal Medicine , Adjunct - Family & Preventive Medicine

Divisions: Public Health , Epidemiology

Lab

Dr. Kenneth Boucher is Co-Director of the Cancer Biostatistics Shared Resource at Huntsman Cancer Institute at the University of Utah. He is a Research Associate Professor in the Department of Internal Medicine and Adjunct Associate Professor in the Department of Family and Preventive Medicine and the Department of Population Health Sciences. He has been at the University of Utah since 1990 and at the Huntsman Cancer Institute since 1996. He is a member of the Cancer Control and Population Sciences Program at HCI.

Dr. Boucher has numerous research interests in the fields of cancer biostatistics and mathematical modeling. These interests include clinical trials, analysis high throughput genomics, carcinogenesis modeling, and cancer epidemiology.

Cancer Biostatistics Shared Resource webpage: https://uofuhealth.utah.edu/huntsman/shared-resources/cancer-biostatistics/

Education History

Undergraduate Washington University
 BS
Graduate Training University of Notre Dame
 MS
Doctoral Training University of Michigan
 PhD

Selected Publications

Journal Article

  1. Pulsipher MA, Wall DA, Grimley M, Goyal RK, Boucher KM, Hankins P, Grupp SA, Bunin (2009). A phase I/II study of the safety and efficacy of the addition of sirolimus to tacrolimus/methotrexate graft versus host disease prophylaxis after allogeneic haematopoietic cell transplantation in paediatric acute lymphoblastic leukaemia (ALL). British journal of haematology, 147(5), 691-9. (Read full article)
  2. Yakovlev A, Boucher K, DiSario (1999). Modeling insight into spontaneous regression of tumors. Mathematical biosciences, 155(1), 45-60. (Read full article)
  3. Li C, Liu T, Tavtigian SV, Boucher K, Kohlmann W, Cannon-Albright L, Grossman (2020). Targeted germline sequencing of patients with three or more primary melanomas reveals high rate of pathogenic variants. Melanoma research, 30(3), 247-251. (Read full article)
  4. Tavtigian SV, Harrison SM, Boucher KM, Biesecker L (2020). Fitting a naturally scaled point system to the ACMG/AMP variant classification guidelines. Human mutation, 41(10), 1734-1737. (Read full article)
  5. Kohli DR, Smith KR, Wong J, Yu Z, Boucher K, Faigel DO, Pannala R, Burt RW, Curtin K, Samadder N (2019). Familial pancreatic cancer risk: a population-based study in Utah. Journal of gastroenterology, 54(12), 1106-1112. (Read full article)
  6. Yakovlev AY, Tsodikov AD, Boucher K, Kerber (1999). The shape of the hazard function in breast carcinoma: curability of the disease revisited. Cancer, 85(8), 1789-98. (Read full article)
  7. Stephens DM, Boucher K, Kander E, Parikh SA, Parry EM, Shadman M, Pagel JM, Cooperrider J, Rhodes J, Mato A, Winter A, Hill B, Gaballa S, Danilov A, Phillips T, Brander DM, Smith SM, Davids M, Rogers K, Glenn MJ, Byrd J (2021). Hodgkin lymphoma arising in patients with chronic lymphocytic leukemia: outcomes from a large multi-center collaboration. Haematologica, 106(11), 2845-2852. (Read full article)
  8. Weldon Gilcrease G, Stenehjem DD, Wade ML, Weis J, McGregor K, Whisenant J, Boucher KM, Thorne K, Orgain N, Garrido-Laguna I, Sharma (2019). Phase I/II study of everolimus combined with mFOLFOX-6 and bevacizumab for first-line treatment of metastatic colorectal cancer. Investigational new drugs, 37(3), 482-489. (Read full article)
  9. Strunck JL, Smart TC, Boucher KM, Secrest AM, Grossman (2020). Improved melanoma outcomes and survival in patients monitored by total body photography: A natural experiment. The Journal of dermatology, 47(4), 342-347. (Read full article)
  10. Rahman H, Kumar D, Liu T, Okwundu N, Lum D, Florell SR, Burd CE, Boucher KM, VanBrocklin MW, Grossman (2021). Aspirin Protects Melanocytes and Keratinocytes against UVB-Induced DNA Damage In Vivo. The Journal of investigative dermatology, 141(1), 132-141.e3. (Read full article)
  11. Cohen AL, Anker CJ, Johnson B, Burt LM, Shrieve DC, Salzman K, Jensen R, Boucher K, Colman (2020). Repeat radiation with bevacizumab and minocycline in bevacizumab-refractory high grade gliomas: a prospective phase 1 trial. Journal of neuro-oncology, 148(3), 577-585. (Read full article)
  12. Agarwal N, Nussenzveig R, Hahn AW, Hoffman JM, Morton K, Gupta S, Batten J, Thorley J, Hawks J, Santos VS, Nachaegari G, Wang X, Boucher K, Haaland B, Maughan B (2020). Prospective Evaluation of Bone Metabolic Markers as Surrogate Markers of Response to Radium-223 Therapy in Metastatic Castration-resistant Prostate Cancer. Clinical cancer research, 26(9), 2104-2110. (Read full article)
  13. Cowman SJ, Fuja DG, Liu XD, Tidwell RSS, Kandula N, Sirohi D, Agarwal AM, Emerson LL, Tripp SR, Mohlman JS, Stonhill M, Garcia G, Conley CJ, Olalde AA, Sargis T, Ramirez-Torres A, Karam JA, Wood CG, Sircar K, Tamboli P, Boucher K, Maughan B, Spike BT, Ho TH, Agarwal N, Jonasch E, Koh M (2020). Macrophage HIF-1¿ Is an Independent Prognostic Indicator in Kidney Cancer. Clinical cancer research, 26(18), 4970-4982. (Read full article)
  14. Cowman SJ, Fuja DG, Liu XD, Tidwell RSS, Kandula N, Sirohi D, Agarwal AM, Emerson LL, Tripp SR, Mohlman JS, Stonhill M, Garcia G, Conley CJ, Olalde AA, Sargis T, Ramirez-Torres A, Karam JA, Wood CG, Sircar K, Tamboli P, Boucher K, Maughan B, Spike BT, Ho TH, Agarwal N, Jonasch E, Koh M (2021). Correction: Macrophage HIF-1¿ Is an Independent Prognostic Indicator in Kidney Cancer. Clinical cancer research, 27(11), 3265. (Read full article)
  15. Wu YP, Boucher K, Hu N, Hay J, Kohlmann W, Aspinwall LG, Bowen DJ, Parsons BG, Nagelhout ES, Grossman D, Mooney K, Leachman SA, Tercyak K (2020). A pilot study of a telehealth family-focused melanoma preventive intervention for children with a family history of melanoma. Psycho-oncology, 29(1), 148-155. (Read full article)
  16. Maughan BL, Kessel A, McFarland TR, Sayegh N, Nussenzveig R, Hahn AW, Hoffman JM, Morton K, Sirohi D, Kohli M, Swami U, Boucher K, Haaland B, Agarwal (2021). Radium-223 plus Enzalutamide Versus Enzalutamide in Metastatic Castration-Refractory Prostate Cancer: Final Safety and Efficacy Results. The oncologist, 26(12), 1006-e2129. (Read full article)
  17. Kelley KC, Grossman KF, Brittain-Blankenship M, Thorne KM, Akerley WL, Terrazas MC, Kosak KM, Boucher KM, Buys SS, McGregor KA, Werner TL, Agarwal N, Weis JR, Sharma S, Ward JH, Kennedy TP, Sborov DW, Shami P (2021). A Phase 1 dose-escalation study of disulfiram and copper gluconate in patients with advanced solid tumors involving the liver using S-glutathionylation as a biomarker. BMC cancer, 21(1), 510. (Read full article)
  18. Drost M, Tiersma Y, Glubb D, Kathe S, van Hees S, Calléja F, Zonneveld JBM, Boucher KM, Ramlal RPE, Thompson BA, Rasmussen LJ, Greenblatt MS, Lee A, Spurdle AB, Tavtigian SV, de Wind (2020). Two integrated and highly predictive functional analysis-based procedures for the classification of MSH6 variants in Lynch syndrome. Genetics in medicine, 22(5), 847-856. (Read full article)
  19. Kircher DA, Trombetti KA, Silvis MR, Parkman GL, Fischer GM, Angel SN, Stehn CM, Strain SC, Grossmann AH, Duffy KL, Boucher KM, McMahon M, Davies MA, Mendoza MC, VanBrocklin MW, Holmen S (2019). AKT1E17K Activates Focal Adhesion Kinase and Promotes Melanoma Brain Metastasis. Molecular cancer research, 17(9), 1787-1800. (Read full article)
  20. Flint ND, Bishop MD, Smart TC, Strunck JL, Boucher KM, Grossman D, Secrest A (2021). Low accuracy of self-reported family history of melanoma in high-risk patients. Familial cancer, 20(1), 41-48. (Read full article)
  21. Tward JD, O'Neil B, Boucher K, Kokeny K, Lowrance WT, Lloyd S, Cannon D, Stephenson RA, Agarwal N, Farr T, Petragallo R, Sherar NZ, Kunz I, Hofer A, Courdy S, Shrieve DC, Dechet (2020). Metastasis, Mortality, and Quality of Life for Men With NCCN High and Very High Risk Localized Prostate Cancer After Surgical and/or Combined Modality Radiotherapy. Clinical genitourinary cancer, 18(4), 274-283.e5. (Read full article)
  22. Rogers CR, Matthews P, Xu L, Boucher K, Riley C, Huntington M, Le Duc N, Okuyemi KS, Foster M (2020). Interventions for increasing colorectal cancer screening uptake among African-American men: A systematic review and meta-analysis. PloS one, 15(9), e0238354. (Read full article)
  23. Holowatyj AN, Haffa M, Lin T, Scherer D, Gigic B, Ose J, Warby CA, Himbert C, Abbenhardt-Martin C, Achaintre D, Boehm J, Boucher KM, Gicquiau A, Gsur A, Habermann N, Herpel E, Kauczor HU, Keski-Rahkonen P, Kloor M, von Knebel-Doeberitz M, Kok DE, Nattenmüller J, Schirmacher P, Schneider M, Schrotz-King P, Simon T, Ueland PM, Viskochil R, Weijenberg MP, Scalbert A, Ulrich A, Bowers LW, Hursting SD, Ulrich C (2020). Multi-omics Analysis Reveals Adipose-tumor Crosstalk in Patients with Colorectal Cancer. Cancer prevention research (Philadelphia, Pa.), 13(10), 817-828. (Read full article)
  24. Okwundu N, Rahman H, Liu T, Florell SR, Boucher KM, Grossman (2021). A randomized double-blind placebo-controlled trial of oral aspirin for protection of melanocytic nevi against UV-induced DNA damage. Cancer prevention research (Philadelphia, Pa.), 15, 129-138. (Read full article)
  25. Chalmers AW, Patel S, Boucher K, Cannon L, Esplin M, Luckart J, Graves N, Van Duren T, Akerley (2019). Phase I Trial of Targeted EGFR or ALK Therapy with Ipilimumab in Metastatic NSCLC with Long-Term Follow-Up. Targeted oncology, 14(4), 417-421. (Read full article)
  26. Kanth P, Boylan KE, Bronner MP, Boucher KM, Hazel MW, Yao R, Pop S, Bernard PS, Delker D (2019). Molecular Biomarkers of Sessile Serrated Adenoma/Polyps. Clinical and translational gastroenterology, 10(12), e00104. (Read full article)
  27. Varedi A, Rahman H, Kumar D, Catrow JL, Cox JE, Liu T, Florell SR, Boucher KM, Okwundu N, Burnett WJ, VanBrocklin MW, Grossman (2020). ASA Suppresses PGE2 in Plasma and Melanocytic Nevi of Human Subjects at Increased Risk for Melanoma. Pharmaceuticals (Basel, Switzerland), 13(1), (Read full article)
  28. Binneboese A, Covington MF, Horn KP, Archibald ZG, Boucher KM, Morton KA, Hoffman J (2021). Correlation between FDG-PET uptake and survival in patients with primary brain tumors. American journal of nuclear medicine and molecular imaging, 11(3), 196-206. (Read full article)
  29. Cohen AL, Neumayer L, Boucher K, Factor RE, Shrestha G, Wade M, Lamb JG, Arbogast K, Piccolo SR, Riegert J, Schabel M, Bild AH, Werner T (2017). Window-of-Opportunity Study of Valproic Acid in Breast Cancer Testing a Gene Expression Biomarker. JCO precision oncology, 1, (Read full article)
  30. Rogers CR, Perdue DG, Boucher K, Korous KM, Brooks E, Petersen E, Inadomi JM, Tuuhetaufa F, Levant RF, Paskett E (2022). Masculinity Barriers to Ever Completing Colorectal Cancer Screening among American Indian/Alaska Native, Black, and White Men (Ages 45-75). International journal of environmental research and public health, 19(5), (Read full article)
  31. Clark KA, Paquette A, Tao K, Bell R, Boyle JL, Rosenthal J, Snow AK, Stark AW, Thompson BA, Unger J, Gertz J, Varley KE, Boucher KM, Goldgar DE, Foulkes WD, Thomas A, Tavtigian S (2022). Comprehensive evaluation and efficient classification of BRCA1 RING domain missense substitutions. American journal of human genetics, 109(6), 1153-1174. (Read full article)
  32. Himbert C, Stephens WZ, Gigic B, Hardikar S, Holowatyj AN, Lin T, Ose J, Swanson E, Ashworth A, Warby CA, Peoples AR, Nix D, Jedrzkiewicz J, Bronner M, Pickron B, Scaife C, Cohan JN, Schrotz-King P, Habermann N, Boehm J, Hullar M, Figueiredo JC, Toriola AT, Siegel EM, Li CI, Ulrich AB, Shibata D, Boucher K, Huang LC, Schneider M, Round JL, Ulrich C (2022). Differences in the gut microbiome by physical activity and BMI among colorectal cancer patients. American journal of cancer research, 12(10), 4789-4801. (Read full article)
  33. Sahu KK, Johnson ED, Butler K, Li H, Boucher KM, Gupta (2022). Improving Bone Health in Patients with Metastatic Prostate Cancer with the Use of Algorithm-Based Clinical Practice Tool. Geriatrics (Basel, Switzerland), 7(6), (Read full article)
  34. Firpo MA, Boucher KM, Bleicher J, Khanderao GD, Rosati A, Poruk KE, Kamal S, Marzullo L, De Marco M, Falco A, Genovese A, Adler JM, De Laurenzi V, Adler DG, Affolter KE, Garrido-Laguna I, Scaife CL, Turco MC, Mulvihill S (2023). Multianalyte Serum Biomarker Panel for Early Detection of Pancreatic Adenocarcinoma. JCO clinical cancer informatics, 7, e2200160. (Read full article)
  35. Gumbleton M, Allan S, Conway H, Boucher K, Marvin J, Hawks J, Burnett W, Van Brocklin M, Whisenant J, Gilcrease G, Gupta (2023). A phase I open-label study of the safety and efficacy of apatinib (rivoceranib) administered to patients with advanced malignancies to improve sensitivity to pembrolizumab in the second- or later-line setting (APPEASE). BMC research notes, 16(1), 16. (Read full article)
  36. Brunsgaard EK, Bowles TL, Asare EA, Grossmann K, Boucher KM, Grossmann A, Jackson JA, Wada DA, Rathore R, Budde G, Grandemange A, Hyngstrom J (2023). Feasibility of personalized circulating tumor DNA detection in stage II and III melanoma. Melanoma research, 33(3), 184-191. (Read full article)
  37. Kunz JN, Huang YJ, Casper AC, Suneja G, Burt LM, Jhingran A, Joyner MM, Harkenrider MM, Small W Jr, Grant JD, Kidd EA, Boucher K, Gaffney D (2023). Dosimetric Evaluation of OARs from SAVE Protocol. International journal of radiation oncology, biology, physics, (Read full article)
  38. Himbert C, Ose J, Gigic B, Viskochil R, Santuci K, Lin T, Ashworth A, Cohan JN, Scaife CL, Jedrzkiewicz J, Damerell V, Atkins KM, Gong J, Mutch MG, Bernadt C, Felder S, Sanchez J, Cohen SA, Krane MK, Hinkle N, Wood E, Peoples AR, Figueiredo JC, Toriola AT, Siegel EM, Li CI, Shibata D, Boucher K, Round JL, Ulrich AB, Schneider M, Huang LC, Hardikar S, Ulrich C (2023). Associations of combined physical activity and body mass index groups with colorectal cancer survival outcomes. BMC cancer, 23(1), 300. (Read full article)
  39. Li H, Sahu KK, Brundage J, Benson M, Swami U, Boucher KM, Gupta S, Hawks J, Sirohi D, Agarwal N, Maughan B (2023). Phase I Trial of Combination Therapy With Avelumab and Cabozantinib in Patients With Newly Diagnosed Metastatic Clear Cell Renal Cell Carcinoma. The oncologist, 28(8), 737-e693. (Read full article)
  40. Covington MF, Hoffman JM, Morton KA, Buckway B, Boucher KM, Rosenthal R, Porretta J, Brownson KE, Matsen CB, Vaklavas C, Ward JH, Wei M, Buys SS, Chittoria N, Yakish ED, Archibald ZG, Burrell LD, Butterfield RI, Yap J (2023). Prospective Pilot Study of (18)F-Fluoroestradiol PET/CT in Patients With Invasive Lobular Carcinomas. AJR. American journal of roentgenology, 221(2), 228-239. (Read full article)
  41. Wen-Ying Wong E, Pandeya S, Crandall H, Smart T, Dixon M, Boucher KM, Florell SR, Grossman D, Sanchez (2023). Electrical Impedance Dermography Differentiates Squamous Cell Carcinoma In Situ from Inflamed Seborrheic Keratoses. JID innovations, 3(3), 100194. (Read full article)
  42. Wagner CB, Boucher K, Nedved A, Micallef IN, Desai S, Hatic H, Goyal G, Zacholski E, Fegley A, Sigmund AM, Bond DA, Samuels C, Kamdar MK, Ba Aqeel S, Torka P, MacDougall K, Borogovac A, Rajeeve S, Sundaram S, Fedak K, Modi D, Travers E, Ayyappan S, Chilakamarri N, Brem EA, Ermann DA, Fitzgerald LA, Hu B, Stephens DM, Shah (2023). Effect of cumulative dose of brentuximab vedotin maintenance in relapsed/refractory classical Hodgkin lymphoma after autologous stem cell transplant: an analysis of realworld outcomes. Haematologica, 108(11), 3025-3032. (Read full article)
  43. Boylan K, Kanth P, Delker D, Hazel MW, Boucher KM, Affolter K, Clayton F, Evason K, Jedrzkiewicz J, Pletneva M, Samowitz W, Swanson E, Bronner M (2023). Three Pathologic Criteria for Reproducible Diagnosis of Colonic Sessile Serrated Lesion Versus Hyperplastic Polyp. Human pathology, 137, 25-35. (Read full article)
  44. Wu YP, Stump TK, Hay JL, Aspinwall LG, Boucher KM, Deboeck PR, Grossman D, Mooney K, Leachman SA, Smith KR, Wankier AP, Brady HL, Hancock SE, Parsons BG, Tercyak K (2023). The family lifestyles, actions and risk education (FLARE) study: Protocol for a randomized controlled trial of a sun protection intervention for children of melanoma survivors. Contemporary clinical trials, 131, 107276. (Read full article)
  45. Wu YP, Tercyak KP, Wankier AP, Brunsgaard EK, Parsons BG, Devine KA, Stump TK, Boucher KM, Hay J (2023). Moderating influences on parents' fatalistic beliefs about cancer and their association with sun safety behaviors among children of melanoma survivors: Implications for treatment. Journal of health psychology, 29(5), 13591053231209167. (Read full article)
  46. Winkler N, Buxton J, Freer P, Raps E, Barraza G, Boucher K, Riegert J, Factor (2023). Comparison of Diagnostic Sensitivity and Procedure-Related Pain of Concurrent Ultrasound-guided Fine-needle Aspiration and Core-needle Biopsy of Axillary Lymph Nodes in Patients with Suspected or Known Breast Cancer. Journal of breast imaging, 5(4), 436-444. (Read full article)
  47. Sahu KK, Li H, Mathew Thomas V, Benson M, Boucher K, Gupta S, Kohli M, Swami U, Agarwal N, Maughan B (2024). A Phase II Study of Rucaparib Monotherapy in Nonmetastatic, Hormone-Sensitive Prostate Cancer Demonstrating "BRCAness" Genotype (ROAR). The oncologist, 29(5), 450-e725. (Read full article)
  48. McKean WB, Yang J, Boucher K, Shrieve DC, Suneja G, Salzman K, Jensen R, Colman H, Cohen A (2024). D-TERMINED, a phase 1 trial in newly diagnosed high-grade glioma with temozolomide, radiation, and minocycline followed by adjuvant minocycline/temozolomide. Neuro-oncology advances, 6(1), vdae063. (Read full article)
  49. Fastner S, Rahman H, Gutierrez J, Shen N, Florell SR, Florell A, Stubben CJ, Boucher KM, Deacon DC, Judson-Torres RL, Grossman (2024). MicroRNA Signatures Associated with Basal Cell Carcinoma Subtypes. JID innovations, 4(4), 100286. (Read full article)
  50. Kohlmann W, Nix DA, Pauley K, Greenberg S, Atkinson A, Boucher KM, Kolesar J, Singer EA, Edge SB, Churchman ML, Graham L, Salhia B, Sanchez A, Zakharia Y, Nepple KG, Schneider BP, Byrne L, Jain RK, Chahoud J, Feng BJ, Gupta (2024). Inherited Germline Variants in Urinary Tract Cancer: A Multicenter Whole-Exome Sequencing Analysis and Correlation With Clinical Features and Tumor Genomics. JCO precision oncology, 8, e2300697. (Read full article)
  51. Wee Y, Wang J, Wilson EC, Rich CP, Rogers A, Tong Z, DeGroot E, Gopal YNV, Davies MA, Ekiz HA, Tay JKH, Stubben C, Boucher KM, Oviedo JM, Fairfax KC, Williams MA, Holmen SL, Wolff RK, Grossmann A (2024). Tumour-intrinsic endomembrane trafficking by ARF6 shapes an immunosuppressive microenvironment that drives melanomagenesis and response to checkpoint blockade therapy. Nature communications, 15(1), 6613. (Read full article)
  52. Vaklavas C, Matsen CB, Chu Z, Boucher KM, Scherer SD, Pathi S, Beck A, Brownson KE, Buys SS, Chittoria N, D'Astous E, Gulbahce HE, Henry NL, Kimani S, Porretta J, Rosenthal R, Ward J, Wei M, Welm BE, Welm A (2024). TOWARDS Study: Patient-Derived Xenograft Engraftment Predicts Poor Survival in Patients With Newly Diagnosed Triple-Negative Breast Cancer. JCO precision oncology, 8, e2300724. (Read full article)
  53. Deacon DC, Stubben C, Marcacci E, Stone CJ, Birdsall M, Florell SR, Boucher K, Grossman D, Judson-Torres R (2024). Classification of Cutaneous Melanoma and Melanocytic Nevi with MicroRNA Ratios Is Preserved in the Acral Melanoma Subtype. The Journal of investigative dermatology, 145(3), 707-709.e2. (Read full article)
  54. Wee Y, Wang J, Wilson EC, Rich CP, Rogers A, Tong Z, DeGroot E, Gopal YNV, Davies MA, Ekiz HA, Tay JKH, Stubben C, Boucher KM, Oviedo JM, Fairfax KC, Williams MA, Holmen SL, Wolff RK, Grossmann A (2023). ARF6-dependent endocytic trafficking of the Interferon-¿ receptor drives adaptive immune resistance in cancer. bioRxiv, (Read full article)
  55. Ulrich CM, Himbert C, Barnes CA, Boucher KM, Daniels B, Bandera VM, Ligibel JA, Wetter DW, Hess R, Kim J, Lundberg K, Mitzman B, Marcus R, Finlayson SRG, LaStayo PC, Varghese TK J (2025). Precision Exercise Effect on Fatigue and Function in Lung Cancer Surgery: A Randomized Clinical Trial. JAMA surgery, 160(5), 495-519. (Read full article)
  56. Galarza Fortuna GM, Grass D, Maughan BL, Jain RK, Dechet C, Beck J, Schuetz E, Sanchez A, O'Neil B, Poch M, Li R, Lloyd S, Tward J, Phunrab T, Hawks JL, Swami U, Boucher KM, Agarwal N, Gupta (2025). Nivolumab adjuvant to chemo-radiation in localized muscle-invasive urothelial cancer: primary analysis of a multicenter, single-arm, phase II, investigator-initiated trial (NEXT). Journal for immunotherapy of cancer, 13(3), (Read full article)
  57. Shen N, Callister A, Florell SR, Florell A, Boucher KM, Frigerio A, Grossman (2025). Recurrence of cutaneous squamous cell carcinoma in situ with follicular involvement. Journal of the American Academy of Dermatology, 93(2), 497-499. (Read full article)
  58. Poppe MM, Boucher K, Gaffney DK, Brownson KE, Smith G, Howell JN, Ticona FF, Kim J, Burt L, Cannon D, Kokeny (2025). NOVEMBER, A Phase 2 Trial of a 9-Day Course of Whole Breast Radiation Therapy With a Simultaneous Lumpectomy Boost for Early-Stage Breast Cancer. International journal of radiation oncology, biology, physics, 123(1), 141-149. (Read full article)
  59. Jain RK, Swami U, Bilen MA, Gebrael G, Boucher KM, Braun E, Brown JT, Chahoud J, Gupta S, Agarwal N, Sonpavde G, Maughan B (2025). Cabozantinib plus Pembrolizumab as First-line Therapy for Cisplatin-ineligible Advanced Urothelial Carcinoma: The PemCab Trial. European urology oncology, 8(4), 952-960. (Read full article)
  60. Glenny EM, Lin T, Bandera VM, Mirminachi B, Khumukcham SS, Gigic B, Warby CA, Aksonova O, Coleman MF, Carpanese A, Busch C, Himbert C, Ose J, Nix DA, Boucher K, Schirmacher P, Strehli I, Hardikar S, Cohan JN, Jedrzkiewicz J, Brobeil A, Schneider MA, Kahlert C, Siegel EM, Byrd DA, Toriola AT, Shibata D, Li CI, Figueiredo JC, Tan AC, Roper J, Ulrich CM, Hursting S (2025). Obesity promotes conserved inflammatory and metabolic transcriptional programs in colon tumors: Evidence from mouse models and the ColoCare Study patient cohort. The American journal of clinical nutrition, 122(6), 1545-1556. (Read full article)
  61. Feng BJ, Kohlmann W, Nix DA, Atkinson A, Boucher KM, Carroll C, Stubben CJ, Kolesar J, Singer EA, Riedlinger G, Edge S, Sahu KK, Churchman M, Graham L, Salhia B, Sanchez A, Zakharia Y, Schneider BP, Jain R, Byrne L, Moskaluk CA, Nepple K, Shabsigh A, Chahoud J, Cairns BR, Gupta (2025). Germline whole-exome sequencing reveals FOXP3-related gene variants conferring urinary cancer susceptibility and associated with immune escape. Journal for immunotherapy of cancer, 13(9), (Read full article)
  62. Wu YP, Stump TK, Deboeck PR, Hay JL, Aspinwall LG, Boucher KM, Grossman D, Mooney K, Leachman SA, Smith KR, Brady HL, Hancock SE, Wankier AP, Tercyak K (2025). Sun protection, sunburn, tanning, and family factors among melanoma survivors and their minor children. Journal of health psychology, 13591053251378226. (Read full article)
  63. Covington MF, Salmon S, Kozlov A, Archibald Z, Butterfield R, Stolk S, Mitchell S, Boucher K, Rosenthal R, Porretta J, Brownson KE, Matsen C, Wei M, Buys S, Vaklavas C, Chittoria N, Buckway B, Meite A, Yap (2025). Staging Invasive Lobular Carcinoma: A Prospective Study on the Efficacy of 18F-Fluoroestradiol (FES)-PET/CT. Clinical breast cancer, 26(1), 36-46. (Read full article)
  64. Becker CA, Mwelwa DWN, Jiang AZ, Huntsman A, Boucher KM, Stubben CJ, Smith EA, Deacon DC, Grossman D, Judson-Torres R (2026). Non-invasive adhesive patch microRNA assay recapitulates tissue biomarkers for melanoma. Clinical and translational medicine, 16(2), e70627. (Read full article)

Letter

  1. Varedi A, Bishop MD, Boucher KM, Kim CC, Grossman (2019). Powering a prospective melanoma chemoprevention trial in high-risk cohorts. International journal of dermatology, 58(11), e232-e234. (Read full article)